ClinicalTrials.gg
CompletedNCT04997122ORUJOSALUD-1Updated Aug 16, 2021

Health Effects of Consuming Olive Pomace Oil

An interventional study of Olive pomace oil and High oleic acid sunflower oil in Healthy and Hypercholesterolemia, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición. Completed at 1 site in Spain. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-16.

Sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Apr 2018, registered Aug 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Hypercholesterolemia with a site in Spain — 5 open to participants now, 11 under way, 7 of them phase 3. Hypercholesterolemia · Spain.

Enrollment
56th of 73
64 · median 300
Started
2018
with 3 others
No phase
14 of 80
2 open now
Registered
59th of 80
by date
Lead sponsor
2 of 80
Instituto de Ciencia y Tecnología de Alimentos y Nutrición

Among the 80 studies in Hypercholesterolemia with a site in Spain, this one is the 56th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2018, is one of 14 with no phase, and was the 59th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

5 of the 80 studies in Hypercholesterolemia with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Hypercholesterolemia with a site in Spain, or all of them as a file.
02

Study summary

Healthy and at risk (hypercholesterolemic) subjects consumed during 4 weeks 45 g/d of either olive pomace oil (OPO) or high oleic acid sunflower oil (HOSO) as the only dietary fat in a randomized, crossover trial. The effects on blood lipids, glucose homeostasis, endothelial function, inflammatory cytokines, oxidative stress biomarkers and anthropometry were measured.

Read the detailed description

This is the first study on the potential health effects of consumption of olive pomace oil.

After a 3-weeks run-in, 34 healthy and 30 hypercholesterolemic subjects were randomized to consume either OPO or HOSO (45 g/d) during 4 weeks, followed by a 3-week wash-out during which volunteers consumed the same amount of normal sunflower oil. During all the study, other dietary sources of fat (oil, nuts, butter, etc.) were restricted. Food intake was monitored by 3-d food records in each intervention stage and volunteers were instructed to maintain their normal physical and dietary habits (except for the changes in the consumption of other oils and fats).

At the beginning and end of each intervention stage, blood and urine samples were obtained, and blood pressure and anthropometric measurements were performed. A complete batch of analysis were performed, including serum lipids, endothelial function (flow mediated dilation (FMD), endothelial nitric oxide synthase (eNOS), vascular (VCAM-1) and intercellular (ICAM-1) cell adhesion molecules, E- and P-selectins), inflammatory and anti-inflammatory cytokines, glucose homeostasis/insulin resistance, antioxidant status and biomarkers of lipid oxidation (malondialdehyde (MDA), LDLox, ferric reducing antioxidant power (FRAP), oxygen radical absorbance capacity (ORAC), ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) quenching capacity) and anthropometry, along with determination of incretins, adipokines, and other clinical and hematological parameters.

03

Conditions studied

  • Healthy
  • Hypercholesterolemia

Keywords

  • Olive pomace oil
  • Lipaemia
  • Glucose homeostasis
  • Inflammation
  • Oxidative stress biomarkers
  • Endothelial function
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers (Total cholesterol \< 200 mg/dL; LDL-cholesterol \< 135 mg/dL)
  • Hypercholesterolemic volunteers (Total cholesterol 200-300 mg/dL; LDL-cholesterol 135-175 mg/dL)

Exclusion criteria

Exclusion Criteria:

  • > 30 Kg/m2
  • Smokers
  • Vegetarians
  • Pregnant women
  • Medication/consumption of vitamins, dietary supplements
  • On antibiotic treatment 3 months before starting the study
  • Digestive disorders/pathologies (gastric ulcer, Chron's disease, inflammatory bowel syndrome, etc.)
  • Food allergies/intolerances
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Olive pomace oil

    Intake of 45 g/d of olive pomace oil as the only source of oil in the diet

    Other: Olive pomace oil

  • Active comparator
    High-oleic sunflower oil

    Intake of 45 g/d of high-oleic sunflower oil as the only source of oil in the diet

    Other: High oleic acid sunflower oil

Interventions

  • OtherOlive pomace oil

    Volunteers consumed during 4 weeks 45 g/d of olive pomace oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.

    Also known as: OPO

  • OtherHigh oleic acid sunflower oil

    Volunteers consumed during 4 weeks 45 g/d of oleic acid-rich sunflower oil as the only source of dietary fat, used for cooking, salad dressing, toasts, etc.

    Also known as: HOSO

06

What researchers measure

Primary outcomes

  1. Blood lipids

    Changes on total or LDL-cholesterol levels or triglycerides in at risk (hypercholesterolemic) subjects. No effect on blood lipids expected in healthy (normocholesterolemic ) volunteers

    Time frame: 4 weeks

Secondary outcomes

  1. Endothelial function

    Changes in the levels of selectins, adhesion molecules or eNOS levels in volunteers

    Time frame: 4 weeks

  2. Blood pressure

    Changes in systolic/diastolic blood pressure in volunteers

    Time frame: 4 weeks

  3. Glucose homeostasis

    Modification of fasting blood glucose or insulin levels, decrease in glycosylated hemoglobin (Hb1Ac), homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) or beta-cell function (HOMA-beta)

    Time frame: 4 weeks

  4. Inflammation

    Changes in pro-inflammatory cytokines/C-reactive protein (CRP) levels

    Time frame: 4 weeks

  5. Oxidative status

    Modification in serum antioxidant capacity (FRAP, ABTS, ORAC) and/or decreased levels of biomarkers of lipid oxidation (MDA, LDLox)

    Time frame: 4 weeks

07

Study locations

1 site
  • Instituto de Ciencia y Tecnología de Alimentos y Nutrición
    Madrid, 28040, Spain
08

References and documents

Publications

  • Gonzalez-Ramila S, Sarria B, Seguido MA, Garcia-Cordero J, Mateos R, Bravo L. Olive pomace oil can improve blood lipid profile: a randomized, blind, crossover, controlled clinical trial in healthy and at-risk volunteers. Eur J Nutr. 2023 Mar;62(2):589-603. doi: 10.1007/s00394-022-03001-y. Epub 2022 Sep 24. PubMed 36153442 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jul 2018, 3 months.

Of 135 non-industry interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's 3 months is below that.

Counting every sponsor, half of 153 studies reached it within 15 months; a quarter within 6 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 9, 2021
StartActual
Apr 2, 2018
Primary completionActual
Jul 13, 2018
CompletionActual
Jul 13, 2018
Last update
Aug 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04997122
Lead sponsor
Instituto de Ciencia y Tecnología de Alimentos y Nutrición
Responsible party
Raquel Mateos (Principal Investigator, Instituto de Ciencia y Tecnología de Alimentos y Nutrición) — Principal investigator
First posted
Aug 9, 2021
Start date
Apr 2, 2018
Primary completion
Jul 13, 2018
Completion
Jul 13, 2018
Last update
Aug 16, 2021

Study contacts

Raquel Mateos, Dr
principal investigator · ICTAN-CSIC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion